Serentis
Cambridge
About Serentis
Serentis develops medical products and drugs. Its products include SRD441, a novel compound that targets endogenous pro-inflammatory and staphylococcus aureus-derived proteases; and SRD174, a topical product designed to produce relief of pruritus. The company’s research programs include SRD326, a topically-applied product for relief from symptoms of Raynaud’s phenomenon; and SRD285 which provides an approach to wound care, promoting enhanced wound healing and local analgesia. Serentis was founded in 2006 and is based in Cambridge, United Kingdom.
Company Facts
- Operating status: Closed
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $30.5M
- Funding stage: Early Stage Venture
- Last round: Series A (Aug 2008)
- Website: serentis-pharma.com
Industries & Categories
Biopharma, Health Care, Medical, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/serentis-1703242 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.